Cell therapy has the potential to reduce the risk of infection after stem cell transplants. The U.S. Food and Drug Administration (FDA) recently approved Omisirge (omidubicel-onlv), a donor-modified…
Read MorePlasma Treatment
FDA’s Plasma Program Data Lacks Cohesion
Informal study hampered by greater than anticipated participation of COVID-19 patients. The U.S. Food and Drug Administration designed a plasma program to try and speed along potential research…
Read More